Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13C6-glipizide
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
13C6-glipizide is a stable isotope-labeled version of glipizide used primarily in pharmacokinetic research studies. It contains six carbon-13 isotopes in place of regular carbon-12 atoms, making it heavier but not radioactive. This labeled compound allows researchers to track drug dissolution and absorption in the gastrointestinal tract when studying modified release formulations of glipizide.
02
Targets
SUR1 (Sulfonylurea receptor 1)KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on 13C6-glipizide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 13C6-glipizide.